Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 10/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | PIM1 | P11309 | 2/20 | 0.52 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7835282 | 1.00 | HPGD (0.58) | HPGDPTPN1POLBMAOAMAOB | |
| SCHEMBL5935568 | 0.84 | HPGD (0.62) | HPGDPTPN1POLBMAOAMAOB | |
| SCHEMBL7013434 | 0.84 | HPGD (0.62) | HPGDPTPN1POLBMAOAMAOB | |
| SCHEMBL6357262 | 0.83 | HPGD (0.61) | HPGDPTPN1POLBMAOAMAOB | |
| SCHEMBL6357256 | 0.83 | HPGD (0.61) | HPGDPTPN1POLBMAOAMAOB | |
| SCHEMBL7822722 | 0.81 | MEN1 (0.55) | MAOAMAOBKDM4EPPARG | |
| SCHEMBL5935589 | 0.78 | HPGD (0.60) | HPGDPTPN1POLBMAOAMAOB | |
| SCHEMBL7010573 | 0.78 | HPGD (0.60) | HPGDPTPN1POLBMAOAMAOB | |
| SCHEMBL5935718 | 0.78 | HPGD (0.56) | HPGDPTPN1POLBMAOAMAOB | |
| SCHEMBL6903005 | 0.74 | PPARG (0.73) | PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0676398-B1 | Heterocyclic compounds having anti-diabetic activity, their preparation and their use | SANKYO CO (JP) | 2001-10-24 | — | — | EP | disclosed |
| US-6117893-A | Heterocyclic compounds having anti-diabetic activity and their use | SANKYO COMPANY, LIMITED (JP) | 2000-09-12 | — | — | US | disclosed |
| EP-1022274-A1 | Oxazolidinedione and Thiazolidinedione derivatves, their preparation and their use | Sankyo Company Limited (JP) | 2000-07-26 | — | — | EP | disclosed |
| US-5977365-A | HYPOGLYCEMIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1999-11-02 | — | — | US | disclosed |
| US-5962470-A | Heterocyclic compounds having anti-diabetic activity and their use | SANKYO COMPANY, LIMITED (JP) | 1999-10-05 | — | — | US | disclosed |
| US-5834501-A | TREATING DIABETES OR HYPERLIPEMIA | SANKYO COMPANY, LIMITED (JP) | 1998-11-10 | — | — | US | disclosed |
| US-5739345-A | HYPOGLYCEMIC AND ANTIDIABETIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1998-04-14 | — | — | US | disclosed |
| US-5624935-A | ANTIDIABETIC AGENTS, HYPOGLYCEMIC AGENTS OR ANTILIPEMIC AGENTS | SANKYO COMPANY, LIMITED | 1997-04-29 | — | — | US | disclosed |
| EP-0676398-A2 | Heterocyclic compounds having anti-diabetic activity, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1995-10-11 | — | — | EP | disclosed |